Scarica l'app Stockscreener
20.00
0.20%
-0.04
Pre-mercato:
20.00
Precedente Chiudi:
$20.04
Aprire:
$20.22
Volume 24 ore:
12,259
Relative Volume:
0.73
Capitalizzazione di mercato:
$35.44M
Reddito:
$8.96M
Utile/perdita netta:
$-9.63M
Rapporto P/E:
-16.90
EPS:
-1.1831
Flusso di cassa netto:
$-15.88M
1 W Prestazione:
-5.68%
1M Prestazione:
+12.87%
6M Prestazione:
+21,154%
1 anno Prestazione:
+11,023%
Intervallo 1D:
$18.20
$20.92
Intervallo di 1 settimana:
$18.20
$21.72
Portata 52W:
$0.0866
$31.00
Palatin Technologies Inc. Stock (PTN) Company Profile
Nome
Palatin Technologies Inc.
Settore
Industria
Telefono
609-495-2200
Indirizzo
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
20.00 | 35.44M | 8.96M | -9.63M | -15.88M | -1.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Laidlaw | Buy |
| 2025-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2015-06-05 | Reiterato | Canaccord Genuity | Buy |
| 2015-01-12 | Reiterato | ROTH Capital | Buy |
| 2012-05-23 | Iniziato | Noble Financial | Buy |
| 2007-01-23 | Iniziato | Next Generation | Buy |
Mostra tutto
Palatin Technologies Inc. Borsa (PTN) Ultime notizie
PTN Stock Price, Quote & Chart | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
PTN Technical Analysis | Trend, Signals & Chart Patterns | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
AuGC reports 94,212-share stake in Palatin Technologies (PTN) - Stock Titan
Palatin Technologies (PTN) Stock: Momentum Signals (Modest Decline) 2026-04-20Social Investment Platform - Cổng thông tin điện tử tỉnh Tây Ninh
Q1 2026 Palatin Technologies Inc Earnings Call Transcript - GuruFocus
Palatin Technologies, Inc. (PTNT) - Minichart
How does Palatin Technologies (PTN) Stock react to market crashes | Price at $18.00, Down 0.11%Dividend Growth - Newser
Palatin Technologies, Inc. (PTN) - Minichart
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI
PTN Technical Analysis & Stock Price Forecast - Intellectia AI
Palatin Technologies (PTNT) Short Interest & Short Float | Updated Apr 2026 $PTNT - MarketBeat
Palatin Technologies stock faces volatility amid bremelanotide sales updates and pipeline advancemen - AD HOC NEWS
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN) - The Globe and Mail
Palatin Technologies (PTNT) Insider Trading Activity 2026 $PTNT - MarketBeat
Palatin Technologies (PTNT) 10K Form and SEC Filings 2026 $PTNT - MarketBeat
PTN Earnings History & Surprises | EPS & Revenue Results | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
PTN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Operating cash flow per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView
EBIT per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView
Dry Eye Disease Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Palatin Technologies, Novaliq, mc2 therapeutics - Barchart.com
PTN Should I Buy - Intellectia AI
Palatin Techs (PTN) Stock Analysis Report | Financials & Insights - Benzinga España
Palatin Technologies (PINK:PTNT) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year - Prader-Willi Syndrome News
Palatin Technologies Q2 Earnings Call Highlights - Defense World
Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - The Globe and Mail
Palatin Technologies, Inc. (AMEX:PTN) Q2 2026 Earnings Call Transcript - Insider Monkey
Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TradingView
Earnings call transcript: Palatin Technologies Q2 2026 reveals challenges By Investing.com - Investing.com South Africa
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising Losses - GuruFocus
Earnings call transcript: Palatin Technologies Q2 2026 reveals challenges - Investing.com Australia
PTN: Strengthened cash position and advanced rare obesity pipeline with key clinical milestones ahead - TradingView
PALATIN TECHNOLOGIES INC SEC 10-Q Report - TradingView
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Malaysian Reserve
PTN | Palatin Technologies, Inc. Analyst Forecasts - Quiver Quantitative
PTN | Palatin Technologies, Inc. Insider Trading - Quiver Quantitative
Palatin Technologies Q2 revenue rises yr/yr, net loss widens - TradingView
PTN: MC4R obesity programs advance to clinical trials as cash position strengthens and net loss widens - TradingView
Palatin funds new obesity drug trials for hypothalamic obesity, PWS - Stock Titan
Palantin Technologies to enact 1-for-50 reverse stock split - MSN
Head-To-Head Contrast: Palatin Technologies (PINK:PTNT) vs. Akorn (OTCMKTS:AKRXQ) - Defense World
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis - Defense World
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - MSN
The Truth About Palatin Technologies (PTN): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Palatin Technologies (PINK:PTNT) Stock Price Passes Above 200-Day Moving Average – Time to Sell? - Defense World
Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN) - TradingView — Track All Markets
Palatin Technologies Inc. Azioni (PTN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):